P1/2, N=320, Not yet recruiting, Dr. Falk Pharma GmbH | N=160 --> 320

P2, N=108, Not yet recruiting, Eye & ENT Hospital of Fudan University

P1, N=116, Active, not recruiting, Columbia University | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2026 --> Dec 2025

We compared against a two-step AAV method, and treated dexamethasone (Dex) during manufacture...Dex augmented the cytotoxic activity of CAR-NK cells by promoting oxidative phosphorylation and ATP production. We designed robust, TGFβ1-resistant allogeneic CAR-NK cells using a virus-free, one-step engineering strategy, establishing a versatile, clinically scalable method for engineering metabolically fortified CAR-NK cells capable of overcoming TME-mediated suppression in solid tumors.

The immune mechanism of its occurrence is still unclear and needs to be further studied. Traditional glucocorticoid is still the first-line drug, but the new targeted drug Efgartigimod has less adverse reactions and faster onset of action, which may become a good choice, but needs to be verified by a larger sample.

P=N/A, N=396, Recruiting, Chiesi Farmaceutica Ltda. | Not yet recruiting --> Recruiting

P3, N=3208, Completed, Children's Hospital of Fudan University | Active, not recruiting --> Completed

Immediate discontinuation of almonertinib combined with intravenous methylprednisolone resulted in significant clinical and radiological improvement within 7 days. This case highlights two important clinical implications: (1) almonertinib-associated ILD can rapidly progress to a life-threatening condition and (2) occupational inhalational exposures (e.g., dust and smoking) have been directly and indirectly implicated as potential risk factors for EGFR-TKI-induced pulmonary toxicity in prior studies and may have contributed to the outcome in this case. Clinicians should maintain heightened vigilance for respiratory complications during almonertinib therapy, particularly in patients with preexisting pulmonary risk factors.

Patients on different GC types (short- vs. long-acting) and on different GC doses (physiologic, moderate, or high dose;18 mg/m2/day hydrocortisone equivalents (HCe), respectively) were compared...In patients with CAH, daily GC dose > 18 mg/m2/day HCe impacts the expression of miRNAs that are known to be associated with GCs and their biological effects. The identification of a distinct circulating miRNA signature associated with supraphysiologic GC exposure in patients with CAH suggests that miRNAs could emerge as a valuable non-invasive biomarker for detecting GC excess and monitoring treatment.

P=N/A, N=22, Completed, Fudan University

P=N/A, N=90, Recruiting, Huazhong University of Science and Technology | Not yet recruiting --> Recruiting

P4, N=420, Recruiting, Rush University Medical Center | Trial primary completion date: Mar 2026 --> May 2026